Pharmacokinetics Clinical Trial
Official title:
An Open-label, Phase I Study to Determine the Safety and Pharmacokinetics of JNJ-26483327, a Multi-targeted Kinase Inhibitor, Administered to Subjects With Advanced Stage and/or Refractory Solid Malignancies
The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies. The absorption, breakdown and elimination of the drug will also be studied.
JNJ-26483327, a multi-targeted reversible kinase inhibitor, is a new drug in development for
treatment of cancer. This study will test the safety (the effect on the body) of
JNJ-26483327 and the highest dose of JNJ-26483327 that patients with advanced cancer can
tolerate will be determined. Antitumor activity of JNJ-26481585 will be evaluated.
JNJ-26483327 will be administered in a continuous regimen (orally twice daily) in 28-day
treatment cycles. The dose of JNJ-26483327 will start low and will be increased during the
study in groups of 1 to 6 patients. If a patient or a group of patients does not have severe
side effects, the next group of patients will get a higher dose. The dose will increase
until some patients have severe side effects. The dose will then be decreased to a dose
level where severe side effects are observed in less than 1/3 of patients. Once a safe dose
level has been determined an additional group of 12-18 patients will be treated. The amount
of JNJ-26483327 in the blood will be measured and the effect of the disease will be
evaluated in all patients.
Patients will be screened for eligibility within 4 weeks before study treatment is given.
The treatment will consist of 28-day treatment cycles in a continuous twice daily dosing
regimen.
During Cycle 1, patients are required to stay in the hospital for 2-3 nights and 2 full
days. In addition there are 5 daytime visits during Cycles 1 and 2 (combined) that may take
up to 6 hours after the morning dose. From Cycle 3 onwards, one hospital visit is required
for each cycle of treatment.
Throughout the study, especially during Cycles 1 and 2, patients will undergo frequent blood
and urine tests, procedures to assess safety including heart function, and tests to assess
the course of the patient's illness. The duration of treatment will depend on adverse
effects and whether there is benefit from the treatment. Two weeks after the last dose of
the study drug, patients are required to return to the study site for follow-up assessments.
Patients will take JNJ-26483327 capsules by mouth twice a day throughout treatment. Patients
will be allowed to continue at the same dose level as long as there are no unacceptable side
effects, and there is benefit to the patient based on the study doctor's evaluations.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04092725 -
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04181008 -
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers
|
Early Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT04406415 -
Oral Nafamostat in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
| Completed |
NCT02534753 -
A Pharmacokinetics Study of Intravenous Ascorbic Acid
|
Phase 1 | |
| Completed |
NCT01682408 -
Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability
|
Phase 1 | |
| Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
| Completed |
NCT01976078 -
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
|
N/A | |
| Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
| Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
| Completed |
NCT01214941 -
Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
|
Phase 4 | |
| Completed |
NCT01260025 -
Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor
|
Phase 1 | |
| Completed |
NCT00983242 -
Drug-Drug Interaction Between Colchicine and Verapamil ER
|
Phase 1 | |
| Completed |
NCT00856570 -
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01276119 -
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
|
Phase 1 | |
| Completed |
NCT00984009 -
A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice
|
Phase 1 | |
| Completed |
NCT01055964 -
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
|
Phase 3 | |
| Completed |
NCT00746499 -
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
|
Phase 1 | |
| Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 |